Title CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
Protocole ID CARMA-BROS
ClinicalTrials.gov ID NCT04151342
Cancer Type(s) Other
Phase Other
Stage
Study Type Other
Drug
Institution CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
City
Principal Investigator Dr. Normand Blais
Coordinator Wiam Belkaid
514-890-8000
Status Recruiting
Activation Date 17-01-2024
Eligibility Criteria
  • Patients ≥ 18 years at cancer diagnosis
  • Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations
  • Accessible/available molecular testing reports/documentation to confirm type(s) of molecular alteration(s) (resulting from the conduct of polymerase chain reaction [PCR] based next generation sequencing [NGS], immunohistochemistry [IHC], fluorescence in situ hybridization [FISH])
  • Canadian resident received follow-up for cancer care in Canada or is currently receiving/planning follow-up for cancer care to occur in Canada at time of enrollment
Exclusion Criteria
  • Previous refusal of the deceased patient, when living, to enroll in this study or patient approached for this study is unable to provide informed consent